Broadly targeted cellular immune responses are thought to be important for controlling replication of human and simian immunodeficiency viruses (HIV and SIV). However, eliciting such responses by vaccination is complicated by immunodominance, the preferential targeting of only a few of the many possible epitopes of a given antigen. This phenomenon may be due to the coexpression of dominant and subdominant epitopes by the same antigen-presenting cell and may be overcome by distributing these sequences among several different vaccine constructs. Accordingly, we tested whether vaccinating rhesus macaques with "minigenes" encoding fragments of Gag, Vif, and Nef resulted in broadened cellular responses capable of controlling SIV replication. We delivered these minigenes through combinations of recombinant Mycobacterium bovis BCG (rBCG), electroporated recombinant DNA (rDNA) along with an interleukin-12 (IL-12)-expressing plasmid (EP rDNA plus pIL-12), yellow fever vaccine virus 17D (rYF17D), and recombinant adenovirus serotype 5 (rAd5). Although priming with EP rDNA plus pIL-12 increased the breadth of vaccine-induced T-cell responses, this effect was likely due to the improved antigen delivery afforded by electroporation rather than modulation of immunodominance. Indeed, Mamu-A*01
T
he HIV epidemic continues to afflict millions of people worldwide. In spite of advances in prevention strategies and the scale-up of antiretroviral therapy access in the last decade, the World Health Organization still recorded more than 6,000 new HIV infections daily in 2012 (1) . Given these statistics and the lack of resources of those countries with the highest number of cases, a prophylactic vaccine is probably the best long-term solution to halt the spread of HIV.
Unfortunately, developing an effective AIDS vaccine has been exceedingly difficult, as evidenced by the disappointing results of most human efficacy trials conducted to date (2) (3) (4) (5) (6) . Although a modest reduction in the rate of HIV acquisition was reported in the RV144 study (7) , this effect was short-lived and will have to be improved in order to significantly impact the size of the pandemic in high-risk areas. The induction of broadly reactive neutralizing antibodies remains a long-sought goal of the HIV vaccine field (8) .
However, the complexity and variability of the HIV Env glycoprotein have frustrated attempts to engender this type of response (9) . Cellular immune responses have also been the focus of many vaccine approaches, since extensive correlative data from HIV-infected patients indicate that virus-specific T cells play a key role in suppressing viral replication and delaying progression to AIDS (10) (11) (12) (13) . Most convincingly, experimental depletion of CD8 ϩ lymphocytes in simian immunodeficiency virus (SIV)-infected rhesus macaques leads to a brisk rise in viremia (14, 15) , implicating these cells in virologic control. Furthermore, for many T-cellbased vaccine regimens, significant reductions in plasma virus concentrations in macaques challenged with pathogenic strains of SIV have been reported (16) (17) (18) (19) (20) . Collectively, these studies support the premise that cellular immunity would improve the efficacy of HIV vaccines.
Exploiting the potential of cellular immunity in HIV vaccine strategies has not been straightforward, due to our limited understanding of the immunological properties of protective T-cell responses (21) . It is still not clear, for instance, which effector functions vaccine-elicited T cells must perform in order to inhibit viral production in vivo. The differentiation state and phenotype of efficacious anti-HIV T cells also need further characterization. Knowledge of these features would provide important clues for the development of HIV immunization strategies, since the amount and duration of antigenic stimulation can directly impact the quality of memory T cells (22) . Additionally, the choice of immunogens for HIV vaccines remains an open question since control of viral replication may be affected, depending on which viral proteins are targeted by the immune system (12, 23) . Although Gag has been a preferred antigen for the induction of cellular immunity, mounting evidence suggests that Vif and Nef might be useful targets as well (24) (25) (26) (27) . Clarifying these issues would provide a rational basis for the design of new vaccine approaches aimed at generating cellular immunity against HIV.
It is widely accepted that HIV vaccines must elicit broad cellular responses to cope with the diversity of circulating isolates (28) (29) (30) . However, the T-cell repertoire is shaped by host-intrinsic immunodominance hierarchies that often favor the expansion of T cells targeting a few "dominant" epitopes while other potentially immunogenic (i.e., "subdominant") sequences are ignored (31) . Interestingly, this phenomenon can be modulated by adjusting immunization regimens so that dominant and subdominant epitopes are not expressed in the same antigen-presenting cell (APC). For example, mouse experiments have shown that inactivating or removing dominant epitopes from immunogens allows the host to respond more effectively to subdominant epitopes (32) (33) (34) . Moreover, isolating epitopes in separate DNA vaccine constructs has been shown to induce equivalent frequencies of T-cell responses directed against dominant and subdominant epitopes (32, 33, 35) . Along these lines, concomitant vaccination with multiple DNA plasmids encoding fragments of a viral protein can broaden the repertoire of virus-specific T-cell responses compared to responses to vectors expressing the full-length antigens (36, 37) . Since this latter strategy is more applicable to HIV vaccine design, we explored it in the present study.
Here we tested the hypothesis that broad T-cell responses elicited by gag, vif, and nef minigene vaccine constructs can control AIDS virus replication. Six minigenes covered parts of the Gag polyprotein, two inserts expressed the amino and carboxyl halves of Vif, and one gene fragment covered the central region of Nef. Each minigene was inserted into individual constructs of the following vector platforms: recombinant Mycobacterium bovis BCG (rBCG), electroporated recombinant DNA (rDNA), yellow fever vaccine virus 17D (rYF17D), and recombinant adenovirus serotype 5 (rAd5). To maximize the immunogenicity of the rDNA vectors, we delivered them by electroporation in the presence of an IL-12-carrying plasmid (EP rDNA plus pIL-12). Macaques in group 1 were immunized with EP rDNA plus pIL-12/rAd5. Animals in group 2 received all vectors in the following combination: rBCG, EP rDNA plus pIL-12, rYF17D, and rAd5. Macaques in group 3 were vaccinated with rYF17D and rAd5, while those in group 4 received rAd5 only. After performing a comprehensive evaluation of the immunogenicity of these vaccine regimens, we assessed their efficacy by challenging all animals with repeated intrarectal inoculations of SIVmac239.
MATERIALS AND METHODS
Research animals. The 39 animals used in this study were Indian rhesus macaques (Macaca mulatta) obtained from the Wisconsin National Primate Research Center (WNPRC). They were cared for in accordance with the guidelines of the Weatherall Report under a protocol approved by the University of Wisconsin Graduate School Animal Care and Use Committee. Vaccinations and SIV challenges were performed under anesthesia, and all efforts were made to minimize suffering. The major histocompatibility complex (MHC) class I genotype of each animal was determined by sequence-specific primer PCR (SSP-PCR) analysis (Table 1 ) (38) . Based on these results, we included two Mamu-A*01 ϩ macaques in each of groups 1 to 4 to facilitate monitoring of vaccine-induced CD8 ϩ T cells. Since Mamu-A*01 expression has been linked to control of SIVmac239 replication (39, 40) , we balanced this effect by including four animals that were positive for this allele in group 5, the control group. Furthermore, none of the animals in this study expressed the MHC class I alleles Mamu-B*08 or Mamu-B*17, which have been associated with elite control of SIV infection (41, 42) . Since combinations of tripartite motif 5 (TRIM5) alleles can restrict replication of certain SIV strains (43, 44) , we determined the TRIM5 genotypes of these animals by sequencing genomic DNA or by SSP-PCR, as described previously (44) .
Vector platforms and immunogens. The nine SIV minigenes employed here encoded the regions of SIVmac239 Gag, Vif, and Nef depicted in Fig. 1A . These sequences were inserted into three vector platforms: rDNA, rYF17D, and rAd5. The rDNA constructs consisted of nine pCMVkan plasmids (45) , each carrying one of the SIV minigenes shown in Fig. 1A . Expression of these gene fragments was under the control of the human cytomegalovirus (CMV) promoter and the bovine growth hormone polyadenylation signal. Except for the two first rDNA vaccinations of group 1, these rDNA vectors were codelivered with the AG157 plasmid, which encodes the two subunits of rhesus IL-12 expressed from two separate transcription units (46) . We refer to this plasmid as pIL-12 here. Aldevron (Fargo, ND) produced the large-scale plasmid batches used for rDNA vaccinations. The nine rAd5 vectors used in these studies contained the same optimized SIV minigenes and were made by Viraquest, Inc., by using the RAPAd method (47) . Of note, the sequences inserted in the rDNA and rAd5 vectors were codon optimized for high expression in mammalian cells.
The nine live-attenuated rYF17D viruses employed were generated as described previously (48) . In sum, SIV minigenes with a codon usage matching that of the YF17D virus were inserted into the junction of the genes encoding E and NS1 in the YF17D backbone. We generated viable viruses by transfecting in vitro-generated, full-length rYF17D genomic mRNA into Vero cells, after which virus present in the supernatant of these cultures was propagated in Vero cell monolayers. We confirmed the presence of all SIV inserts in their corresponding rYF17D viruses by reverse transcription-PCR analysis of the E/NS1 intergenic region and by nucleotide sequencing.
The rBCG constructs contained SIV inserts that were slightly different than those mentioned above; instead of nine SIV minigenes, a total of 14 codon-optimized sequences covered the following amino acid regions of the SIVmac239 Gag, Vif, and Nef proteins: gag-1 (amino acids [aa] 6 to 52), gag-2 (aa 44 to 84), gag-3 (aa 76 to 123), gag-4 (aa 142 to 186), gag-5 (aa 178 to 227), gag-6 (aa 239 to 358), vif-1 (aa 1 to 60), vif-2 (aa 51 to 110), vif-3 (aa 102 to 160), vif-4 (aa 151 to 214), nef-1 (aa 45 to 96), nef-2 (aa 88 to 139), nef-3 (aa 131 to 180), and nef-4 (aa 172 to 210). Each of these gene fragments was inserted into individual rBCG vectors.
Vaccinations. In order to maximize the dispersal of our SIV inserts among different lymph nodes and thereby avoid immunodominance (32, 35) , we delivered each of the nine rDNA, rYF17D, and rAd5 constructs to separate anatomical locations. These sites were rotated in subsequent immunizations so that each location did not receive vectors encoding the same SIV minigene twice. The sequence and timing of these vaccinations are shown in Fig. 1B .
For the rDNA vaccinations, we prepared individual syringes containing 1.0 mg of each rDNA and two different amounts of pIL-12, depending on the vaccination group. We used phosphate-buffered saline (PBS) to adjust the volume of these syringes to 0.5 ml. Macaques in group 1 did not receive pIL-12 at the first and second EP rDNA vaccinations. At the third occasion, we added 0.4 mg of pIL-12 to each syringe containing the rDNA constructs, yielding a total of 3.2 mg of pIL-12. For group 2, 0.08 mg of pIL-12 was codelivered with each of the rDNA plasmids, yielding a total of 0.64 mg of pIL-12 given at each EP rDNA vaccination. The TriGrid in vivo electroporation system developed by Ichor Medical Systems, Inc. (San Diego, CA) was used to administer the rDNA constructs intramuscularly, using standard 1-ml syringes with a 22-gauge needle. The rDNA constructs were injected into the right and left legs (tibialis), right and left thighs (lower and upper lateralis), and right and left forearms (brachialis), yielding a total of eight injection sites. We combined the rDNA plasmids carrying the gag (aa 6 to 52) and nef (aa 45 to 210) minigenes and codelivered them during the EP vaccinations. Macaques in group 4 were vaccinated three times with a single dose of empty DNA (1.0 mg; no pIL-12) delivered to a separate muscle on each occasion.
Vaccinees in groups 2 and 3 were vaccinated with 2.0 ϫ 10 5 PFU of each rYF17D construct. Each construct was diluted in PBS to a final volume of 1.0 ml and injected subcutaneously (using 27-gauge needles) into one of the following anatomical sites: right and left shoulders, right and left forearms, right and left thighs, right and left calves, and abdomen. Macaques in group 4 received a single dose of the parental YF17D vaccine (2.0 ϫ 10 5 PFU) in the right forearm. All animals in groups 1 to 4 were vaccinated with 10 11 viral particles of each of the nine rAd5 vectors carrying the SIV minigenes. These constructs were diluted in 0.5 ml of PBS and delivered intramuscularly using 25-gauge needles. The same sites were used as for the EP rDNA vaccinations, with the addition of the left shoulder.
Macaques in group 2 were vaccinated once with rBCG. As described above, the SIV inserts expressed by the rBCG vectors were broken down into additional fragments, yielding a total of 14 individual constructs. We resuspended 2.0 ϫ 10 5 CFU of each rBCG vector in 100 l of PBS and injected the mixtures intradermally into nine different sites: right and left calves, right and left thighs, right and left arms, right and left shoulders, and abdomen.
SIVmac239 challenges. We challenged the animals in this study by using repeated, intrarectal (i.r.) inoculations of SIVmac239 of 800 50% tissue culture infective doses (TCID 50 ) per exposure, corresponding to 6.52 ϫ 10 6 viral RNA (vRNA) copies. We exposed the macaques to SIV every week and assessed plasma viral loads 7 days after each inoculation to determine if they had acquired SIV infection. If viral loads were Ն1,000 vRNA copies/ml of plasma, animals were considered to be infected and were not rechallenged. If viral loads were Ͻ1,000 vRNA copies/ml of plasma, we obtained an additional measurement at day 9 or 10 to ensure productive infection. If viral loads were positive at this second measurement, we did not rechallenge the animals; however, if they were negative, we resumed the i.r. inoculations at day 14. After eight exposures with the initial dose of 800 TCID 50 per challenge, several animals remained uninfected, and so we increased the challenge inoculum as shown in Table 2 .
IFN-␥ enzyme-linked immunosorbent spot (ELISPOT) assays. We isolated peripheral blood mononuclear cells (PBMC) from EDTA-treated blood by using Ficoll-Paque Plus (GE Health Sciences) density centrifugation. We used PBMC or PBMC depleted of CD8 ϩ cells (CD8 Ϫ PBMC) by magnetic bead separation (Miltenyi Biotec, Auburn, CA), directly in precoated ELISpotPLUS kits (Mabtech Inc., Mariemont, OH) for the detection of monkey gamma interferon (IFN-␥) according to the manufacturer's protocols. Briefly, 10 5 PBMC or CD8 Ϫ PBMC were used per well and incubated for 14 to 18 h at 37°C in 5.0% CO 2 . As a positive control, 5.0 g/ml of concanavalin A (Sigma Chemical, St. Louis, MO) was added to the cells, and a set of negative control wells of medium only was also included on each plate. Peptide pools of 10 15-mers overlapping by 11 amino acids spanning the regions of SIVmac239 Gag (n ϭ 11 pools), Vif (n ϭ 5 pools), and Nef (n ϭ 4 pools) covered by the minigenes were used at a concentration of 1.0 M. Reactivity to each protein is reported as the We delivered the SIV minigenes through four vaccine regimens comprised of combinations of three vector platforms (rBCG, EP rDNA plus pIL-12, and rYF17D) followed by a common rAd5 boost. Each SIV minigene was inserted into an individual vector, yielding a total of nine constructs for each vector platform. The rBCG vectors were an exception, as they contained smaller SIV minigenes and thus required 14 different constructs to cover the same regions of Gag, Vif, and Nef described above. At week 14 to 25 after the rAd5 boost, we began challenging the animals intrarectally with 800 TCID 50 of SIVmac239. Animals were inoculated every week, and viral loads were assessed 7 days after each challenge. If an animal was not productively infected after a given virus exposure, it was rechallenged the following week. Since several animals remained uninfected after eight inoculations with 800 TCID 50 , we increased the dose of the inoculum according to the information provided in Table 2 .
sum of responses to these pools. ICS assay. We performed a multiparameter intracellular cytokine staining (ICS) assay by incubating freshly isolated PBMC from rhesus macaques with pools of Gag, Vif, and Nef peptides, as previously described (49) . Samples were acquired using FACS DIVA, version 6.2, on a special order research product (SORP) BD LSR II apparatus equipped with a 50-mW 405-nm violet, a 100-mW 488-nm blue, and a 50-mW 640-nm red laser, and results were analyzed by using FlowJo 9.4 (TreeStar, Inc.). Analysis and presentation of distributions were performed with Microsoft Excel and GraphPad Prism. In the prechallenge assays, we incubated PBMC with the same pools of Gag, Vif, and Nef peptides employed in the IFN-␥ ELISPOT assays (see above). For data analysis, we first gated on forward scatter height (FSC-H) versus forward scatter area (FSC-A) to remove doublets (see Fig. S1 in the supplemental material). Subsequently, we gated on the lymphocyte population and then created a dump channel by excluding CD14 ϩ CD19 ϩ events. At this stage, we separated lymphocyte subsets based on their expression of either CD4 or CD8 (excluding those expressing both markers) and conducted our functional analyses within these two compartments. After making gates for each function (IFN-␥, CD107a, TNF-␣, and IL-2), we used the Boolean gate platform to generate a full array of possible combinations, equating to 16 response patterns when testing four functions (2 4 ϭ 16). We used three criteria to determine positivity of responses: (i) background-subtracted responses had to be at least 2-fold higher than the background itself; (ii) Boolean gates for each response pattern had to contain Ն10 events; (iii) response patterns had to be greater than matched values obtained in ICS assays using PBMC from three SIV-naive Indian rhesus macaques stimulated under the same conditions.
Viral load measurements. Viral loads were measured from EDTA anticoagulated plasma by using a previously described protocol (50). The limit of reliable quantification as performed on an input volume of 0.5 ml of plasma is 30 copy equivalents of SIV genomic RNA per ml.
Statistical analyses. We utilized the IFN-␥ ELISPOT data for comparisons of SIV-specific T-cell responses among the four vaccinated groups. We carried out pairwise permutation tests in which 10,000 permutation samples were generated by swapping the group labels. P values were obtained according to the two-sample t statistic. To confirm the results obtained by the permutation tests, we also performed Mann-Whitney tests and obtained similar P values. To maintain the type I error rate at no higher than ␣, we applied the Bonferroni-Holm correction to these comparisons and obtained a corrected threshold of 0.0015.
We defined each animal's peak viral load as the highest viral load measurement during the first 4 weeks of infection. Set point viremia was determined as the geometric mean of viral loads measured within weeks 6 to 12 postinfection. To determine vaccine efficacy, we compared viral loads from each of groups 1 to 4 with that of group 5, the control group. We performed pairwise comparisons of the groups by using permutation tests. For each test, 10,000 permutations samples were generated by permuting the vaccination group labels. We obtained P values by using the customary two-sample t statistic. The threshold of significance for the viral load comparisons was 0.0026 according to the Bonferroni-Holm adjustment.
To determine whether vaccination affected the rate at which animals acquired SIV infection, we used Kaplan-Meier survival analyses to test whether vaccinees in each of groups 1 to 4 and control animals in group 5 differed in the number of challenges required until infection. All comparisons yielded P values of Ͼ0.3, according to log rank tests. For our correlates analysis, we compared nine immunological variables with each animal's set point viral loads by using the Spearman rank correlation test (see Table 3 , below). We obtained P values from 1,000 bootstrap resamples from the observed pairs of values.
RESULTS

Vaccination regimens. Previous studies have shown that dividing dominant and subdominant epitopes among different rDNA vectors during vaccination can overcome natural immunodominance hierarchies and result in equivalent CD8
ϩ T-cell responses to both types of epitopes (32, (35) (36) (37) . Here, we applied this strategy to a T-cell-based SIV vaccine in an attempt to broaden the repertoire of vaccine-elicited T-cell responses. We hypothesized that vaccination with minigenes encoding fragments of the SIVmac239 Gag, Vif, and Nef proteins would generate broadly targeted T-cell responses capable of controlling viral replication after mucosal challenge with SIVmac239. To test this hypothesis, we designed a total of nine minigenes, six of which covered parts of the matrix (MA), capsid (CA), p2, and nucleocapsid (NC) of the Gag polyprotein (Fig. 1A) . Two inserts covered the entire Vif ORF, while one sequence encoded the central part of Nef (Fig. 1A) . We delivered these minigenes by using four vector platforms: rBCG, EP rDNA plus pIL-12, rYF17D, and rAd5. Each minigene was inserted into a separate vaccine vector, yielding a total of nine constructs for each vector platform. The only exception was rBCG, for which we had 14 different constructs (6 for Gag, 4 for Vif, and 4 for Nef; see Materials and Methods). In order to maximize the dispersal of antigens among different lymph nodes, we administered each vaccine vector to a separate anatomical site and rotated these locations in subsequent immunizations so that constructs encoding fragments of the same protein were not administered at the same site twice.
We immunized a total of 31 Indian rhesus macaques with four different heterologous prime-boost regimens comprising combinations of the vaccine vectors mentioned above. Animals in group 1 (n ϭ 8) received three EP rDNA primes, with pIL-12 given only at the third immunization (Fig. 1B) . Of note, animals in this group experienced lymphopenia in the weeks that followed the third administration of EP rDNA plus pIL-12, which was likely caused by the high dose of pIL-12 (3.2 mg) delivered on that occasion (51) . To ensure that the animals had sufficient time to recover, we administered the rAd5 boost 26 weeks later (Fig. 1B) . Macaques in group 2 (n ϭ 8) were vaccinated with all four vectors, given in the following order: rBCG, EP rDNA plus pIL-12, rYF17D, and rAd5 (Fig. 1B) . Importantly, the dose of pIL-12 delivered to group 2 vaccinees was 5-fold lower (0.64 mg) than that employed in group 1 and did not cause any observable adverse events. Group 3 animals (n ϭ 8) received the same rYF17D prime and rAd5 boost reported recently (27) .
The fact that macaques in groups 1 to 3 were boosted with rAd5 might have masked the contributions of their priming immunizations to their overall SIV-specific T-cell response, since rAd5 is highly immunogenic in nonhuman primates (52) . To control for this, macaques in group 4 (n ϭ 7) were primed with "empty" versions of the DNA (without pIL-12) and YF17D constructs described above, and then animals were boosted with the same rAd5 vectors given to groups 1 to 3 (Fig. 1B) . This way, rAd5 was the sole source of Gag-, Vif-, and Nef-specific T-cell responses in the group 4 animals, providing a reference for assessing the immunogenicity and efficacy of the vaccine regimens employed in groups 1 to 3. Macaques in group 5 (n ϭ 8) did not receive any vaccination regimen and served as controls for the present study (Fig. 1B) .
Immunogenicity of vaccination regimens. We assessed the immunogenicity of the four vaccine regimens by carrying out IFN-␥ ELISPOT and ICS assays at several time points following the rAd5 boost, including the time of challenge. The IFN-␥ ELISPOT assays, performed on PBMC and CD8 Ϫ PBMC, provided a quantitative readout for comparing cellular responses among the groups ( Fig. 2 ; see also Fig. 4, below) . To complement this analysis, we set up ICS assays at the same time points to characterize the functional profiles of vaccine-induced CD4 ϩ and CD8 ϩ T cells (Fig. 3) . The immunogenicity and efficacy data for each of groups 1, 2, 3, 4, and 5 are color coded with blue, green, beige, black, and red symbols, respectively.
The rAd5 boost resulted in vigorous expansion of Gag-and Vif-specific cellular responses in groups 1 and 2 ( Fig. 2A and B) . Nef was also targeted, but at lower frequencies (Fig. 2) . Notably, vaccinees in both groups mounted impressive CD4 ϩ T-cell responses at day 7 post-rAd5 boost ( Fig. 2A) , with total medians of spot-forming cells exceeding 6,000 SFC/10 6 CD8 Ϫ PBMC (Fig.  2C) . In addition to IFN-␥, these SIV-specific CD4 ϩ T cells were also capable of elaborating TNF-␣ and IL-2, but not CD107a (Fig.  3A and C) . By day 14 post-rAd5 boost, CD4
ϩ T-cell responses had contracted to less than half of their peak levels recorded at day 7 ( Fig. 2B and D) , while the number of SFC/10 6 PBMC remained high (Fig. 2B ). This implied that SIV-specific CD8 ϩ T lymphocytes predominated at this time point. Indeed, contemporary ICS measurements confirmed this pattern and revealed that production of IFN-␥ either alone or in conjunction with CD107a were the main functional signatures of vaccine-induced CD8 ϩ T cells on this occasion (Fig. 3B and D and data not shown) . Importantly, vaccinees in groups 1 and 2 maintained readily detectable SIVspecific T-cell responses until the time of challenge (total medians, Ͼ950 SFC/10 6 PBMC), with CD4 ϩ T cells still comprising a substantial fraction of their total response (Fig. 4A) . Of note, the total magnitude of cellular responses in these two groups was statistically indistinguishable at all prechallenge time points analyzed ( Fig. 2C and D and 4B ), in spite of substantial differences in the vaccinations that preceded the rAd5 boost.
Vaccine-induced T-cell responses in groups 3 and 4 were of lower frequencies than those detected in groups 1 and 2 but conformed to a similar pattern; Gag and Vif were preferentially targeted, and the peak expansion of CD4 ϩ and CD8 ϩ T-cell responses occurred at days 7 and 14 post-rAd5 boost, respectively ( Fig. 2A and B) . Concomitant ICS assays demonstrated that SIVspecific CD4 ϩ and CD8 ϩ T lymphocytes in groups 3 and 4 were infrequent and less heterogeneous than their counterparts in groups 1 and 2 ( Fig. 3E to H) . Not surprisingly, statistical comparisons of the total magnitude of cellular responses measured in the four groups confirmed the superior immunogenicity of the group 1 and group 2 regimens compared to those given to groups 3 and 4 ( Fig. 2C and D and 4B ). This analysis also revealed that the total frequencies of SIV-specific T cells in groups 3 and 4 were similar, except for a modest increase in the number of IFN-␥-producing cells measured in PBMC from group 3 animals at day 14 post-rAd5 boost (P ϭ 0.0446) (Fig. 2D) . Of note, this difference was not significant after correcting for multiple comparisons. The similarity in the total sizes of the group 3 and group 4 responses suggests that the rYF17D vaccination did not effectively prime SIV-specific T cells in the group 3 animals. Indeed, only a few group 3 vaccinees had measurable SIV-specific T cells at day 14 post-rYF17D vaccination (see Fig. S2D in the supplemental material). This finding is consistent with a recent study conducted in
FIG 2
Immunogenicity of vaccine regimens at days 7 and 14 post-rAd5 boost. We carried out IFN-␥ ELISPOT assays on PBMC and CD8-depleted (CD8 Ϫ PBMC) at days 7 (A and C) and 14 (B and D) after the rAd5 boost by using peptide pools spanning the regions of SIVmac239 Gag, Vif, and Nef covered by the nine minigenes. The magnitude of each animal's vaccine-induced T-cell response to Gag, Vif, and Nef is shown in panels A and B. Response values were calculated as described in Materials and Methods. The total SIV-specific T-cell response for each animal comprises the sum of IFN-␥-producing cells in PBMC or CD8
Ϫ PBMC that were stimulated by the Gag, Vif, and Nef peptide pools at day 7 (C) or 14 (D) post-rAd5 boost. We compared the total magnitudes of these responses among the four groups by using pairwise permutation tests. The threshold of significance for these comparisons was 0.0015 according to the Bonferroni-Holm adjustment. Groups 1, 2, 3, and 4 are color coded in blue, green, beige, and black, respectively. Lines represent medians, and each symbol corresponds to one vaccinee.
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July 2014 Volume 88 Number 13 jvi.asm.org 7499 our laboratory that showed that rYF17D vectors are poorly immunogenic in rhesus macaques (49) . As for the persistence of these responses, we detected low frequencies of vaccine-elicited T cells in both group 3 and group 4 animals at the time of challenge ( Fig.  4A and B) .
We determined the total breadth of vaccine-induced T-cell responses in all animals at day 21 post-rAd5 boost (Fig. 5) . To do that, we performed IFN-␥ ELISPOT in PBMC using deconvoluted peptide pools for which positive responses were observed at days 7 and/or 14 after the rAd5 boost. This allowed us to map T-cell ϩ T cells at their peak expansion, we performed this analysis at days 7 and 14 after the rAd5 boost, respectively. Response magnitudes for each animal were calculated by adding the percentages of Gag-, Vif-, and Nef-specific CD4 ϩ or CD8 ϩ lymphocytes producing each combination of functions tested. Panels on the left correspond to CD4 ϩ T-cell responses in group 1 (A), group 2 (C), group 3 (E), and group 4 (G). Panels on the right correspond to CD8 ϩ T-cell responses in group 1 (B), group 2 (D), group 3 (F), and group 4 (H). Results for groups 1, 2, 3, and 4 are color coded in blue, green, beige, and black, respectively. responses down to single 15-mers, depending on blood availability. Remarkably, vaccinees in groups 1 and 2 recognized a total median of 23 and 22 epitopes, respectively, which were concentrated in Gag, followed by Vif and Nef (Fig. 5A) . These values were significantly greater than the total number of responses targeted by macaques in group 3 (median, 14 epitopes) and group 4 (median, 9 epitopes) (Fig. 5A and B) . Of note, the majority of Gagspecific T-cell responses elicited in groups 1 to 4 targeted the parts of CA, p2, and NC encoded by the gag (aa 178 to 258) and gag (aa 250 to 415) minigenes (see Fig. S3 in the supplemental material) . (53, 54) . The two vif minigenes were equally immunogenic in all groups, while most Nef-specific T cells were directed against the central part of the nef minigene (see Fig. S3 in the supplemental material) .
The exceptional breadth of responses measured in the group 1 and group 2 animals prompted us to characterize the contribution of CD4 ϩ and CD8 ϩ T cells to their repertoire of vaccine-elicited cellular responses. Although the approach mentioned above yielded high sensitivity for mapping individual T-cell responses in each animal, we could not discriminate between the two subsets in the IFN-␥ ELISPOT assays performed on whole PBMC. We addressed this issue by calculating the total number of pools of peptides recognized by CD4 ϩ and CD8 ϩ T cells in the ICS assays performed at days 7 and 14 post-rAd5 boost, respectively. Each one of these pools contained 10 15-mers overlapping by 11 amino acids spanning the regions of Gag (n ϭ 11 pools), Vif (n ϭ 5 pools), and Nef (n ϭ 4 pools) covered by the minigenes. We found that, on average, vaccine-elicited CD4 ϩ T cells in groups 1 and 2 recognized 70% of these pools, compared to 23% and 14% for groups 3 and 4, respectively (data not shown). This difference was less pronounced in the CD8 ϩ T-cell compartment; while vaccinees in groups 1 and 2 mounted CD8 ϩ T cells against 42% of the pools of Gag, Vif, and Nef peptides, this number reached 37% for group 3 and 26% for group 4 (data not shown).
The high frequency CD4 ϩ T cells engendered in groups 1 and 2 stemmed from priming those animals with rDNA delivered by electroporation, which has been shown to dramatically improve the immunogenicity of gene-based vaccines (55) (56) (57) (58) (59) (60) . Indeed, electroporation is highly efficient at transfecting cells in vivo and can increase gene expression levels by 100-to 1,000-fold above levels for intramuscular injection of rDNA without electrical stimulation (61) . Along these lines, we detected sizeable SIV-specific Tcell responses in the majority of vaccinees in groups 1 and 2 after the last EP rDNA plus pIL-12 and prior to the rAd5 boost (see Fig.  S2A to C in the supplemental material). Thus, priming with EP rDNA resulted in robust expansion of broad, high-frequency, and multifunctional cellular responses after the rAd5 boost in the group 1 and group 2 vaccinees. Most of these vaccine-induced cellular responses were comprised of CD4 ϩ T cells, although CD8
ϩ T lymphocytes contributed a sizable fraction as well.
Vaccine-induced CD8
؉ T-cell responses to Mamu-A*01-restricted dominant and subdominant epitopes in groups 1 to 4. The gene fragmentation strategy employed here attempted to circumvent immunodominance by dispersing dominant and subdominant epitopes among different APCs in order to broaden the T-cell repertoire induced by vaccination. Previous studies in the murine we carried out IFN-␥ ELISPOT assays on PBMC using deconvoluted Gag, Vif, and Nef peptide pools for which a positive IFN-␥ ELISPOT response was observed at previous time points. Since the 15-mers that comprise each peptide pool overlap by 11 amino acids, we avoided overestimating the breadth of T-cell responses by considering a minimum of two consecutive positive peptides as one response. (A) Number of unique responses in Gag, Vif, and Nef recognized by vaccinees in groups 1 to 4. (B) The total breadth was calculated by adding the number of responses directed against Gag, Vif, and Nef measured within each animal. The resulting number was used for comparing the breadth of vaccine-induced T-cell responses among groups 1 to 4. We used pairwise permutation tests for this analysis, and the threshold of significance for these comparisons was 0.0015 according to the Bonferroni-Holm adjustment. Groups 1, 2, 3, and 4 are color coded in blue, green, beige, and black, respectively. Lines represent medians, and each symbol denotes one vaccinee.
model have shown that this approach induces equivalent responses to both types of epitopes (32, (35) (36) (37) . Using this rationale, we investigated whether the immunization regimens employed in groups 1 to 4 affected the immunodominance hierarchy of known SIV-specific CD8 ϩ T-cell epitopes. For this analysis, we focused on the two Mamu-A*01 ϩ macaques present in each group, since this MHC class I molecule binds many SIVmac239-derived peptides with defined immunodominance patterns (62, 63) . We used IFN-␥ ELISPOT assay to assess reactivity against the immunodominant Gag 181-189 CM9 epitope as well as several other subdominant epitopes in Gag (Gag 149 -157 LW9, Gag 254 -262 QI9, and Gag 372-379 LF8) and Vif (Vif 100 -109 VL10 and Vif 144 -152 QA9) (Fig. 6) . Nef-derived peptides capable of binding to Mamu-A*01 at physiologically relevant 50% inhibitory concentrations have not been described. We found that all Mamu-A*01 ϩ vaccinees in groups 1 to 4 mounted CD8 ϩ T-cell responses to Gag 181-189 CM9 and Vif 100 -109 VL10, though over a wide spectrum of frequencies (Fig. 6) . Responses to the other subdominant epitopes were either undetectable or at borderline levels, as was the case with rh2036's response to Gag 372-379 LF8 at day 14 post-rAd5 boost (Fig. 6B) . Strikingly, vaccine-elicited CD8 ϩ T cells to the immunodominant Gag 181-189 CM9 epitope were either below or close to the threshold of positivity of our IFN-␥ ELISPOT assay (50 SFC/10 6 PBMC) in the group 1 vaccinees (Fig. 6A) . In contrast, these animals had easily detectable Vif 100 -109 VL10-specific CD8 ϩ T cells after the rAd5 boost, which outnumbered the Gag 181-189 CM9 response at all time points analyzed (Fig. 6A) . In macaques in groups 2 to 4, these responses conformed to a different immunodominance pattern whereby both Gag 181-189 CM9-and Vif 100 -109 VL10-specific CD8 ϩ T cells peaked at similar frequencies but the expansion kinetics of the latter cells appeared protracted compared to the Gag-directed response ( Fig. 6B to D) .
With only two Mamu-A*01 ϩ macaques in each group, it is difficult to conclude whether these data reflect bona fide changes to the immundominance ranks of the Gag 181-189 CM9 and Vif 100 -109 VL10 epitopes or are simply due to biological variability among the animals. However, the fact that the immunodominance hierarchy adopted by these responses in the two group 1 animals was the opposite of what is typically seen during primary SIVmac239 infection of Mamu-A*01 ϩ macaques suggests that the former scenario is more likely.
Mucosal challenge with SIVmac239. In order to approximate clinically relevant human exposures to HIV, we challenged all animals intrarectally with repeated inoculations of SIVmac239 sufficient to infect only a fraction of challenged animals per occasion (64) . These challenges began after various intervals after the rAd5 boost that ranged from 14 to 25 weeks (Fig. 1B) . We determined the initial dose of our inoculum based on a previous in vivo titration study conducted in our laboratory and on the results of a recent efficacy trial (60) , which utilized the same SIVmac239 stock used here. In that study, Winstone et al. reported that all macaques in their control group became infected after seven intrarectal challenges with 800 TCID 50 (60) . We therefore chose this dose as our starting point.
After a series of eight weekly challenges with 800 TCID 50 , three vaccinees in group 1, five in group 2, six in group 3, four in group 4, and four control animals in group 5 became productively infected ( Table 2 ). Given that several macaques remained uninfected after this first challenge phase, we increased the dose of the SIVmac239 inoculum to 4,000 TCID 50 for the next 6 weeks. During this time, all vaccinees in groups 1 to 4 (except for rh2001 in group 1) and two control animals acquired SIV infection (Table  2) . Notably, two control macaques, r02076 and r03111, remained uninfected after this second round of challenges. We then began a third series of challenges with 5,000 TCID 50 for the next 4 weeks, which was sufficient to infect r02076 after two exposures (Table  2) . Nevertheless, rh2001 and r03111 resisted these four challenges with 5,000 TCID 50 . These animals finally became infected after we increased the dose of the SIVmac239 inoculum to 50,000 TCID 50 , which infected rh2001 and r03111 after two and four exposures, respectively ( Table 2) . Of note, none of the vaccination regimens tested in the present study affected acquisition of SIVmac239 infection (Fig. 7) .
To assess vaccine efficacy, we compared viral loads between vaccinees in groups 1 to 4 and the control animals in group 5 during the acute and chronic phases of infection. Our significance threshold for these comparisons was 0.0026, as established by the Bonferroni-Holm correction for multiple testing. SIVmac239 replicated vigorously in the group 5 macaques, reaching a median peak viral load of 1.2 ϫ 10 7 vRNA copies/ml of plasma and then plateauing at 6.9 ϫ 10 5 vRNA copies/ml ( Fig. 8E to H) . The majority of vaccinated macaques also experienced high levels of viral replication in the acute phase (Fig. 8A to D) , with median peak viral loads ranging from 4.4 ϫ 10 6 vRNA copies/ml in group 4 to 7.1 ϫ 10 6 vRNA copies/ml in group 2 (Fig. 8G ). The similarity of these peak viremia values among the groups was unexpected, given the marked differences in cellular immunity induced by the four immunization regimens (Fig. 2C and D) . Of note, two vaccinees controlled acute-phase viremia to less than 10 5 vRNA copies/ml; rh2001 in group 1 and rh1969 in group 4 had peak viral loads of 1.4 ϫ 10 4 and 4.6 ϫ 10 4 vRNA copies/ml, respectively. Nevertheless, in spite of these two outliers, median peak viral loads in groups 1 to 4 were statistically indistinguishable from that of group 5 (Fig. 8G) .
Encouragingly, several vaccinees controlled viral replication in the chronic phase. This effect was most evident in group 1, with three macaques (rh2001, r05061, and r98006) experiencing viral loads of less than 10 3 vRNA copies/ml at week 12 postinfection (Fig. 8A) . Overall, the median set point viral load for this group was 5.7 ϫ 10 4 vRNA copies/ml, corresponding to a significant 1-log reduction in virus production compared to group 5 (P ϭ 0.002) (Fig. 8H) . Macaques in group 2 performed similarly and lowered set point viremia to a median of 7.5 ϫ 10 4 vRNA copies/ml (P ϭ 0.006) (Fig. 8H ). Although the P value for this comparison was slightly above our significance threshold, the difference in set points between groups 2 and 5 appears biologically significant, considering the distribution of viral loads among animals within each group (Fig. 8B and E) . As for group 3, chronicphase viremia in those animals plateaued at a median of 1.9 ϫ 10 5 vRNA copies/ml and was not statistically distinct from that of the control group (Fig. 8C, F, and H) . Strikingly, group 4 had the lowest median set point of all vaccinated groups (1.6 ϫ 10 4 vRNA copies/ml), and two of its animals (r04022 and r03115) had plasma viral loads below 10 3 vRNA copies/ml at weeks 8 and 12 postinfection ( Fig. 8D and H) . This outcome was quite surprising, given how unremarkable the cellular immune responses induced in the group 4 animals were. However, perhaps because of the smaller sample size of this group, the median set point viral load in group 4 was not statistically distinct from that of group 5 at the Bonferroni-Holm-corrected level (P ϭ 0.018) (Fig. 8H) .
We also evaluated whether combinations of TRIM5 alleles ex-pressed by vaccinees in groups 1 to 4 impacted the outcome of this trial. The TRIM5 gene encodes a cytoplasmic protein (TRIM5␣) that interacts with the HIV/SIV capsid early after infection and restricts viral replication (65 Fig. 9A and B) . Furthermore, expression of restrictive TRIM5 genotypes was not linked to the exceptionally high number of i.r. challenges required to infect the group 1 vaccinee rh2001 (TRIM5 Q/Q ) and the group 5 macaques r02076 (TRIM5 Q/TFP ) and r03111 (TRIM5 Q/TFP ). These results are consistent with previous reports showing that SIVmac239 is refractory to the antiviral effects of TRIM5␣ (43, 44) .
In sum, none of the vaccination regimens employed in groups 1 to 4 delayed acquisition of SIV infection or affected peak viremia. Vaccine-induced T-cell responses in groups 1 and 2 were partially effective in the chronic phase, affording a modest 1-log reduction in set point viral loads. Unexpectedly, macaques in group 4 also controlled viral replication at this stage, but the 1.6-log reduction in median set point achieved in this group was not significant after correcting for multiple comparisons. Even though the immunogenicity of the group 1 and group 2 regimens surpassed that obtained in group 4 by all T-cell measurements employed here (i.e., magnitude of IFN-␥-producing T cells, breadth, and ability to perform multiple immunological functions), these groups lowered viral loads to nearly the same extent. The similarity in these outcomes underscores our limited understanding of the T-cell correlates of virologic control of immunodeficiency virus infection.
Anamnestic responses and correlates analysis. We evaluated anamnestic cellular responses by performing IFN-␥ ELISPOT and ICS assays at day 14 postinfection. We found that vaccine-induced T-cell responses in all groups underwent robust expansion after infection, reaching levels that surpassed those measured in the vaccine phase (Fig. 2 and 10) . The magnitude of these responses was considerably higher in PBMC than in CD8
Ϫ PBMC, indicating a predominance of CD8 ϩ T cells at this stage ( Fig. 10A and B) . Similar to the pattern observed during the vaccinations, Gag and Vif were preferentially targeted by the majority of the animals (Fig.  10A) . Interestingly, the total frequency of SIV-specific T cells in groups 1 and 2 no longer outnumbered those in groups 3 and 4; instead, all groups had largely equivalent levels of anamnestic cellular responses after infection, except for a mild increase in the magnitude of the group 2 response in PBMC compared to that in groups 1 and 3 (Fig. 10B) .
The ICS analysis confirmed that CD8 ϩ T cells greatly outnumbered CD4
ϩ T cells at this time point, likely due to the depletion of the latter subset caused by the high levels of viral replication that vaccinees experienced in the acute phase (Fig. 11) . The functional profile of anamnestic CD8 ϩ T-cell responses was similar among the four groups and resembled the phenotype observed during the vaccine phase, with the majority of the cells producing two or more functions (Fig. 11B, D, F , and H). One exception was that several animals in groups 1 to 4 mounted CD8 ϩ T cells that stained positive for CD107a alone after infection; these cells were not detected after the rAd5 boost. As for CD4 ϩ T cells, two functional signatures distinguished prechallenge and postchallenge responses. First, while IL-2-producing CD4 ϩ T cells were easily detected after the rAd5 boost, they nearly disappeared following SIV infection (Fig. 11A, C , E, and G). This phenomenon might be due to a preferential depletion of this subtype, as IL-2-producing CD4 ϩ T cells have been shown to be highly susceptible to lentivirus infection (66) . Second, cytotoxic (CD107a ϩ ) CD4 ϩ T cells, which were not detected during the vaccine phase, expanded to considerable levels in several group 1 and group 2 vaccinees after infection ( Fig. 11A and C) . This phenotype was typically accompanied by the simultaneous production of IFN-␥ and TNF-␣. Indeed, IFN-␥ ϩ TNF-␣ ϩ CD107a ϩ CD4 ϩ T cells were detected in half of the group 2 vaccinees at day 14 postinfection (Fig. 11C ). Of Table 2 shows the percentage of uninfected vaccinees in each of groups 1 to 4 or control animals in group 5 after each intrarectal inoculation with SIVmac239. Animals were inoculated with 800 TCID 50 in challenges 1 to 8, 4,000 TCID 50 in challenges 9 to 14, 5,000 TCID 50 in challenges 15 to 18, and 50,000 TCID 50 in challenges 19 to 22. The rate at which vaccinees in groups 1 to 4 acquired SIV infection was not significantly different from that of control animals in group 5, as determined by the log rank test (P Ͼ 0.3).
note, a few investigators have reported cytolytic CD4 ϩ T cells in HIV-1-infected patients, and these responses have recently been linked to improved control of HIV replication and delayed progression to AIDS (67) (68) (69) . However, the magnitude of SIV-specific CD4 ϩ T cells that stained positive for CD107a did not correlate with either peak or set point viral loads in the present study (data not shown).
Since vaccination may have altered the immunodominance hierarchy of the Gag 181-189 CM9 and Vif 100 -109 VL10 epitopes in some of the Mamu-A*01 ϩ vaccinees, we examined the expansion kinetics of vaccine-induced CD8 ϩ T-cell responses to these peptides after infection. As a reference, we carried out this analysis early after infection of the four unvaccinated Mamu-A*01 ϩ macaques in group 5 and confirmed that CD8 ϩ T cells directed against Gag 181-189 CM9 dominated over those specific for Vif 100 -109 VL10 at all time points investigated (Fig. 12A) . At weeks 2 and 3 postinfection, all Mamu-A*01 ϩ vacccinees mounted recall CD8 ϩ T-cell responses to Gag 181-189 CM9, albeit over a wide range of frequencies (Fig. 12B to E) . In the group 2 macaques, for instance, responses against this immunodominant epitope exceeded 10,000 SFC/10 6 PBMC (Fig. 12C) , while r03084 in group 1 had a peak Gag 181-189 CM9-specific CD8 ϩ T-cell response of Ͻ2,000 SFC/10 6 PBMC (Fig. 12B) . Animal r05061 in group 1 and the group 4 vaccinee r03115 also responded less robustly to this epitope ( Fig. 12B and E) . The fact that r03084, r05061, and r03115 had Gag 181-189 CM9-specific CD8 ϩ T cells below the limits of detection at the time of challenge might explain their lower anamnestic responses against this epitope (Fig. 6A and D) . Interestingly, CD8 ϩ T cells to the Vif 100 -109 VL10 epitope adopted two patterns of expansion after infection: they either matched or surpassed the size of their contemporaneous Gag 181-189 CM9-specific response, as seen in both group 1 animals (Fig. 12B) , the group 2 macaque rh2036 (Fig. 12C) , rh2034 in group 3 (Fig. 12D), and r03021 in group 4 (Fig. 12E) , or underwent limited proliferation, reverting to their typical subdominant status (e.g., r03043, r98036, and r03115 in groups 2, 3, and 4 respectively) (Fig. 12C to E) . The magnitude of these responses was also related to their frequency before infection, as the former animals had the highest numbers of Vif 100 -109 VL10-specific CD8 ϩ T cells at the time of the first SIV challenge (Fig. 6 ). These results demonstrate that vaccine-induced CD8 ϩ T cells directed against a subdominant epitope can expand to high levels after SIV infection. However, the magnitude of the anamnestic Vif 100 -109 VL10-specific CD8 ϩ T-cell response did not seem to affect acute-phase viremia in the present study; except for r05061 (group 1) and r03021 (group 4), the remaining vaccinees mounting high frequencies of these Vif-specific CD8 ϩ T cells experienced peak viral loads that exceeded 10 6 vRNA copies/ml (Fig. 8G) . Furthermore, the magnitude of vaccine-induced Vif 100 -109 VL10-specific CD8 ϩ T cells measured at the day of the first challenge did not correlate with set point viral loads in Mamu-A*01 ϩ vaccinees (see Fig.  S4A in the supplemental material) .
Lastly, we carried out a correlates analysis in an attempt to understand the basis of the partial virologic control reported here. Since none of the vaccine regimens significantly reduced the acute-phase viremia compared to the control group, we focused on set point viral loads only. For this analysis, we selected nine immunological variables that were measured either in the vaccine phase or after the animals became infected (day 14 postinfection). These variables included the total magnitude and breadth of vaccine-induced T-cell responses, as determined by IFN-␥ ELISPOT assays on PBMC and CD8 Ϫ PBMC, and the percentage of polyfunctional CD4 ϩ and CD8 ϩ T-cell responses, defined as cells staining positive for at least three functions. Of note, we could not analyze whether the number of CD4 ϩ or CD8 ϩ T-cell responses elicited by vaccination was associated with virologic control, because our approach to determine T-cell breadth was based on IFN-␥ production by PBMC in ELISPOT assays. Strikingly, none of the immunological parameters mentioned above correlated with set point viremia (Table 3) . Moreover, the breadth of Gag-, Vif-, and Nef-specific T-cell responses measured after vaccination and the total number of responses recalled during the acute phase of infection were not associated with set point viral loads either (see Fig. S4B to E). Together, these results demonstrate that neither the breadth nor magnitude nor polyfunctionality of vaccineinduced, SIV-specific T-cell responses dictated the outcome of this trial.
DISCUSSION
In this study, we attempted to overcome immunodominance and ultimately improve the breadth of a T-cell-based SIV vaccine by delivering immunogens as minigenes rather than full-length ORFs. Since coexpression of dominant and subdominant epitopes within the same APC appears to be important for immunodominance (70, 71) , dividing these epitopes by gene fragmentation has been shown to induce broadly targeted cellular immunity in mice (32, (35) (36) (37) . We designed nine minigenes encoding fragments of the SIVmac239 Gag, Vif, and Nef proteins and delivered them to rhesus macaques by using combinations of rBCG, EP rDNA plus pIL-12, and rYF17D vectors followed by a common rAd5 boost. The group 1 (EP rDNA plus pIL-12/rAd5) and group 2 (rBCG/EP
FIG 11
Functional profile of anamnestic T-cell responses. We carried out multiparameter ICS assays at day 14 postinfection to determine the ability of anamnestic SIV-specific T cells to degranulate (i.e., CD107a expression) and produce cytokines (IFN-␥, TNF-␣, and IL-2). The antigen stimuli for these assays consisted of peptide mixtures spanning (i) amino acids 1 to 291 and (ii) 281 to 510 of the Gag polyprotein, (iii) the Vif ORF, and (iv) the Nef ORF. Each symbol denotes one vaccinee and corresponds to the total frequency of Gag-, Vif-, and Nef-specific T cells capable of producing each combination of functions tested. Panels on the left correspond to CD4 ϩ T-cell responses in group 1 (A), group 2 (C), group 3 (E), and group 4 (G). Panels on the right correspond to CD8 ϩ T-cell responses in group 1 (B), group 2 (D), group 3 (F), and group 4 (H). Groups 1, 2, 3, and 4 are color coded in blue, green, beige, and black, respectively. rDNA plus pIL-12/rYF17D/rAd5) regimens achieved the best immunogenicity and induced broad and abundant cellular immune responses. The group 3 (rYF17D/rAd5) and group 4 (rAd5) vaccine modalities also elicited SIV-specific T-cell responses, but their levels were significantly lower. The superior immunogenicity of the group 1 and group 2 regimens stemmed from immunizing these animals with rDNA delivered by electroporation, an extremely effective way to engender T-cell immunity (61) . Notably, EP rDNA has been shown to elicit broad and high-frequency cellular immune responses in humans, even without the benefit of a heterologous viral vector boost (59) . Moreover, the ability of EP rDNA to induce T-cell responses can be further increased by the coadministration of molecular adjuvants, such as the IL-12-expressing plasmid used here (46, 55, 60) . These observations corroborate the efficiency of electroporated rDNA immunizations to prime cellular immune responses. Of note, we did not formally address whether the gene fragmentation strategy employed here improved the overall breadth of vaccine-induced T-cell responses compared to delivering the Gag, Vif, and Nef immunogens as whole ORFs. This would require a head-to-head comparison of the immunogenicities of each of the four vaccine regimens tested in groups 1 to 4 with those achieved by the same vector combinations encoding full-length Gag, Vif, and Nef, a prohibitively expensive experiment. However, inferences can be made from past studies conducted in our laboratory that used similar vaccine modalities encoding full-length, codon-optimized SIVmac239 antigens. For example, rDNA priming (delivered by conventional intramuscular injection) followed by a rAd5 boost encoding the entire SIVmac239 proteome (except for Env) elicited a median of 8 Gag-specific T-cell responses (20) . Critically, the number of these responses was calculated according to the same approach we used to determine the T-cell breadth in the present study and, for this comparison, we only considered epitopes lying within the same regions covered by the six Gag minigenes. We found that this number was significantly lower than the median of 11 epitopes recognized by the group 1 and group 2 vaccinees in the current study (P Ͻ 0.05). An important caveat of this analysis is the difference in the way the rDNA vectors were delivered in the two trials, which makes it difficult to conclude whether the superior breadth achieved by the group 1 and group 2 regimens was due to the gene fragmentation strategy and/or the fact that the rDNA constructs were administered via electroporation. In this regard, we carried out a more straightforward analysis by comparing the number of Gag-specific T-cell responses induced in the group 4 animals with that achieved by another rAd5-based vaccine reported recently (49) . While the Gag immunogen was delivered to group 4 macaques in fragments through six distinct rAd5 vectors, only one rAd5 construct expressing full-length Gag was given to animals in the study in question. We found that vaccinees in both cases recognized a similar number of Gag pools covering the same regions as the minigenes (P ϭ 0.77). Also, the breadth of Gag-directed responses was indistinguishable between group 4 and recipients of a homologous rAd5 prime-boost regimen aimed at recapitulating the immunization protocol employed in the Step trial (P ϭ 0.95) (72) . It should be noted that these comparisons still suffer from caveats, such as differences in the total number of immunogens chosen for each study and potential competition between epitopes located within rAd5-derived proteins and the SIV inserts. Notwithstanding these limitations, these data imply that the gene fragmentation strategy tested here did not significantly expand the breadth of vaccine-induced T-cell responses and that priming with EP rDNA was the decisive factor for the broad T-cell repertoire elicited in groups 1 and 2.
A related goal was to determine whether gene fragmentation was able to engender responses to epitopes that are subdominant during primary SIVmac239 infection. For this analysis, we monitored if Mamu-A*01 ϩ vaccinees in groups 1 to 4 developed CD8 ϩ T cells to five Mamu-A*01-restricted epitopes with previously defined immunodominance hierarchies (62, 63) . In addition to the dominant Gag 181-189 CM9 determinant, only one subdominant epitope (Vif 100 -109 VL10) was consistently recognized by the Mamu-A*01 ϩ vaccinees. Despite some variability in their expansion kinetics, CD8 ϩ T cells targeting these epitopes peaked at sim- ilar levels within each Mamu-A*01 ϩ macaque in groups 2 to 4. The group 1 vaccinees were an exception, as they had barely detectable CD8 ϩ T cells targeting Gag 181-189 CM9, while their contemporaneous Vif 100 -109 VL10-specific responses reached modest to high frequencies. This analysis emphasizes the difficulty of overcoming immunodominance by vaccination. Likewise, a recent attempt by our group to induce epitope-specific subdominant CD8 ϩ T cells by using both novel and traditional vector platforms also met with limited success (73) . Thus, maneuvers other than gene fragmentation may be required to significantly alter immunodominance hierarchies of vaccine-induced CD8 ϩ T-cell responses in primates.
The inability of rAd5 to boost Gag 181-189 CM9-specific CD8 ϩ T cells in the two Mamu-A*01 ϩ macaques in group 1 was intriguing, since these responses underwent robust expansion in MHC class I-matched vaccinees in groups 2 and 3. This unusual pattern may be due to the lymphopenia experienced by group 1 animals after their third EP rDNA immunization, which was associated with the large dose of the IL-12-expressing plasmid delivered at that occasion. Given that exogenous administration of recombinant IL-12 has been shown to abrogate immunodominance of CD8 ϩ T-cell responses in mice (74) , it is possible that the overdose of IL-12 produced shortly after the last EP rDNA immunization perturbed the immunodominant rank of the Gag 181-189 CM9-specific CD8 ϩ T-cell response elicited in the Mamu-A*01 ϩ vaccinees in group 1. We determined vaccine efficacy by challenging all animals in groups 1 to 4, plus eight unvaccinated control macaques (group 5), with repeated, titered inoculations of SIVmac239 via the intrarectal route. This regimen aimed at simulating clinically relevant human exposures to HIV-1 through anal receptive intercourse (64). Our efficacy endpoints included reductions in peak and set point viral loads compared to those in group 5. Although our study was not adequately powered to detect an effect on SIV acquisition rates, we conducted this analysis anyway and found no difference between vaccinated and control groups. Unfortunately, none of the four vaccine regimens tested here affected peak viremia. It should be noted, however, that it is exceedingly difficult to contain acute-phase viral replication following rectal transmission of SIV, and presumably HIV-1. Even in experimentally controlled settings, in which SIV inoculations are performed atraumatically, viral particles can rapidly penetrate the rectal epithelia and disseminate to other organs. Indeed, Ribeiro dos Santos et al. recently reported that SIV can reach mucosal lymphoid aggregates and colic lymph nodes as early as 4 h after challenge (75) . Alarmingly, PBMC-associated SIV DNA was detected 20 h later. Given this fast entry kinetics, AIDS vaccine approaches should elicit immune responses not only at mucosal sites of transmission but also in lymph nodes where virus amplification can occur.
Vaccinees in groups 1 and 2 significantly reduced set point viral loads by 1 log compared to group 5. This reduction was more pronounced in group 1. Of note, Winstone et al. recently reported robust protection in macaques vaccinated with an EP rDNA plus pIL-12 prime followed by a rAd5 boost encoding the entire SIVmac239 proteome (60) . After repeated intrarectal challenges with the same SIVmac239 stock and dose used in the present study, vaccinees decreased peak and set point viral loads by 2.6 and 4.4 logs, respectively, compared to the mock-immunized group. Moreover, two immunized animals remained uninfected after 13 challenges. This level of control is substantially better than the outcome observed in groups 1 and 2 here. Variations in the dose of pIL-12 given to the group 1 macaques and the additional recombinant vectors used in group 2 may have contributed to these divergent outcomes. However, a more likely explanation for the positive results reported by Winstone et al. is that their vaccine encoded an envelope protein that was identical in amino acid sequence to that of the challenge virus. Consequently, in addition to mounting cellular responses directed against all viral proteins, those vaccinees were also equipped with Env-specific antibodies that probably provided an extra line of defense against the virus. While these data suggest that combining cellular and humoral immunity can improve the efficacy of HIV-1 vaccine regimens, engendering these responses will require novel vector platforms in light of the futility of all rAd5-based human vaccines tested so far (2, 4, 5) .
The group 1 and group 2 vaccine regimens generated high frequencies of SIV-specific CD4 ϩ T cells, which participate in key immunological processes, including antibody production and generation of CD8 ϩ T-cell responses (76) (77) (78) . Interestingly, we observed that vaccine-elicited CD4 ϩ T cells in groups 1 and 2 demonstrated different functional profiles before and after SIV infection. While the majority of SIV-specific CD4 ϩ T cells elaborated IL-2 following the rAd5 boost, this subset was virtually absent at day 14 postinfection. This change in phenotype was likely due to the elimination of IL-2-secreting CD4 ϩ T cells after infection, since production of this cytokine has been associated with a higher susceptibility to HIV replication (66) . We also noticed that a considerable fraction of the anamnestic SIV-specific CD4 ϩ Tcell responses expanding after infection of group 1 and group 2 vaccinees comprised CD107a ϩ CD4 ϩ T cells. Strikingly, CD4 ϩ T cells displaying this cytolytic phenotype were not detected during the vaccine phase. Of note, similar phenotypic changes in CD4 ϩ T-cell responses have been observed in one human subject who was vaccinated with a recombinant canarypox vector and later acquired HIV-1 infection (79) . Notably, Soghoian et al. recently described cytolytic virus-specific CD4 ϩ T cells during acute HIV-1 infection (69) . Further characterization of these cells revealed that they were capable of inhibiting HIV replication in vitro and were associated with delayed progression to AIDS. However, in contrast to these findings, the magnitude of SIV-specific CD107a ϩ CD4 ϩ T-cell responses in the present study did not correlate with improved outcome after infection (data not shown). Overall, these results have implications for the evaluation of CD4 ϩ T-cell responses induced by HIV-1 vaccine strategies, as the phenotype of these responses might change early after infection.
The single rAd5 immunization delivered to group 4 macaques also afforded a modest (1.6-log) reduction in their median set point compared to that in group 5, but this difference was not significant after correcting for multiple comparisons. This outcome was rather surprising, given that group 4 vaccinees developed the lowest levels of SIV-specific cellular responses after vaccination. While homologous rAd5 vaccination has been largely ineffective in stringent monkey trials (18, 72, 80) , including more antigens to this regimen, in addition to Gag, has been shown to result in more favorable outcomes (19, 20) . Thus, the fact that group 4 animals were vaccinated not only with Gag but also with Vif and Nef sequences might explain their partial control of chronic-phase viremia. Importantly, since the rAd5 immunization was the only source of SIV-specific T-cell responses in these animals, group 4 can serve as a reference to evaluate the contribution of the additional immunizations used in groups 1 to 3 to their outcome after challenge. Notably, the median peak and set point viral loads in groups 1 to 3 were similar, if not superior, to those in group 4. The proximity of these outcomes indicates that the rBCG, EP rDNA plus pIL-12, and rYF17D vectors administered to vaccinees in groups 1 to 3, despite augmenting their overall SIV-specific T-cell responses, did not enhance their ability to control viral replication. Although larger sample sizes would be required to validate this hypothesis, our data suggest that increasing the magnitude, breadth, and functional heterogeneity of vaccine-induced T-cell responses does not necessarily translate into greater antiviral activity. Likewise, none of the nine immunological parameters included in our correlates analysis was associated with control of chronic-phase viremia, confirming that conventional T-cell measurements are poor predictors of vaccine efficacy against AIDS virus infection (21, 81). Indeed, the homologous rAd5 regimens employed in the STEP and Phambili trials and the rDNA prime/rAd5 boost assessed in the recent HVTN 505 study did not afford any protection against HIV-1 infection and yet induced acceptable levels of T-cell responses in the majority of vaccinees (2, 4, 5, 82) . Collectively, these results stress the difficulty of harnessing the potential of cellular immunity in vaccine strategies without knowledge of the immunological correlates of T-cell-mediated control of AIDS virus replication.
In conclusion, here we tested whether vaccinating rhesus macaques with minigenes expressing fragments of Gag, Vif, and Nef would result in broadly targeted T-cell responses capable of controlling SIV replication. We delivered these minigenes through combinations of rBCG, EP rDNA plus pIL-12, rYF17D, and rAd5 vectors arranged in four distinct immunization protocols. Vaccinees in groups 1 and 2, who were primed with EP rDNA plus pIL-12, developed the highest levels of SIV-specific T-cell responses. A close examination of CD8 ϩ T-cell responses elicited in Mamu-A*01 ϩ animals and comparisons between the present experiment and previous SIV efficacy trials conducted in our laboratory suggested that the gene fragmentation strategy employed here had only a minor impact on immunodominance. Unfortunately, none of the four vaccine regimens decreased peak viremia after repeated mucosal challenges with SIVmac239, but a modest (1-log) reduction in set point viral loads was observed in groups 1, 2, and possibly 4. These findings are relevant for the development and testing of new HIV-1 vaccine modalities, since they demonstrate that broad, high-frequency, and polyfunctional T-cell responses elicited by conventional vector platforms may not be sufficient to substantially decrease AIDS virus replication. We thank Jerald C. Sadoff for providing the rBCG constructs used in this study. We are also thankful to Barbara Felber and George Pavlakis for providing the AG157 plasmid used in the electroporated rDNA vaccinations. We are also grateful to Chrystal Glidden, Gretta Borchardt, and Debra Fisk for MHC and TRIM5 typing of animals, and Saverio Capuano III, Eric Peterson, and Kristin Crosno for providing excellent care of the rhesus macaques used in this study. We thank the AIDS Research and Reference Reagent Program for providing the SIVmac239 peptides used in our immunological assays.
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